Candidozyma auris: Identification, antifungal susceptibility, and caspofungin-induced paradoxical growth
- 22 January 2026
- journal article
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 60, 101065
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Candida auris—a systematic review to inform the world health organization fungal priority pathogens listMedical Mycology, 2024
- Candida auris – Comparison of sensititre YeastOne and Vitek 2 AST systems for antifungal susceptibility testing – A single centre experienceIndian Journal of Medical Microbiology, 2024
- Rapid Environmental Contamination With Candida auris and Multidrug-Resistant Bacterial Pathogens Near Colonized PatientsClinical Infectious Diseases, 2023
- Echinocandin Resistance in Candida auris Occurs in the Murine Gastrointestinal Tract Due to FKS1 MutationsAntimicrobial Agents and Chemotherapy, 2023
- Strategies to Prevent Transmission of Candida auris in Healthcare SettingsCurrent Fungal Infection Reports, 2023
- Head‐to‐head comparison of CLSI, EUCAST, Etest and VITEK®2 results for Candida auris susceptibility testingInternational Journal of Antimicrobial Agents, 2022
- Candida auris Fungemia and a local spread taken under control with infection control measures: First report from TurkeyIndian Journal of Medical Microbiology, 2021
- Understanding Echinocandin Resistance in the Emerging Pathogen Candida aurisAntimicrobial Agents and Chemotherapy, 2018
- Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff ValuesAntimicrobial Agents and Chemotherapy, 2017
- A rare case of breakthrough fungal pericarditis due to fluconazole‐resistant Candida auris in a patient with chronic liver diseaseJMM Case Reports, 2014